SCHEMBL4650899

SCHEMBL4650899

CCN(C(=O)CC(NS(=O)(=O)c1ccccc1)c1ccc(OCC(=O)O)c(C(=O)O)c1)c1c[nH]c2ccc(OC)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
GRK2 P25098 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
MMP2 P08253 7/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 2/20 0.40
MMP13 P45452 2/20 0.40
MMP14 P50281 2/20 0.40
ADAM17 P78536 2/20 0.40
GAA P10253 1/20 0.40
MMP9 P14780 6/20 0.40
KMT2A Q03164 4/20 0.37
FPR1 P21462 1/20 0.37
KCNA5 P22460 3/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650946 0.94 POLB (0.44) POLBTDP1GRK2DUSP3PTPN5
SCHEMBL7050666 0.85 POLB (0.40) POLBTDP1GRK2DUSP3PTPN5
SCHEMBL4651292 0.79 ATM (0.38) POLBTDP1GRK2DUSP3PTPN5
SCHEMBL4651316 0.75 ALDH1A1 (0.48) POLBMMP2ALDH1A1MMP9KMT2A
SCHEMBL4650872 0.73 ALDH1A1 (0.60) POLBALDH1A1GAAKMT2ATP53
SCHEMBL7050019 0.72 ALDH1A1 (0.54) POLBALDH1A1KMT2ATP53MEN1
SCHEMBL4650893 0.71 MAPT (0.53) TDP1MMP2MAPTALDH1A1MMP13
SCHEMBL4650884 0.70 PTPN1 (0.49) MMP2ALDH1A1MMP14MMP9
SCHEMBL4651379 0.70 ALDH1A1 (0.58) POLBMAPTALDH1A1GAAKMT2A
SCHEMBL7053662 0.69 ALDH1A1 (0.47) POLBMMP2ALDH1A1MMP9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301474-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS Array Biopharma Inc. (US) 2003-04-16 EP claimed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US claimed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO claimed
EP-1301474-B1 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC (US) 2008-09-10 EP disclosed
US-6586467-B2 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus ARRAY BIOPHARMA INC. 2003-07-01 US disclosed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040003-A1 Preparation of phosphatase inhibitors PTPRS, PTPRO, PTPRR POLB 3603/4885TDP1 982/4885GRK2 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.